PT-141 (Bremelanotide) research guide for Garbutt. Melanocortin-4 receptor agonist studied for sexual function — covers purity standards, COA testing, and sourcing.
For anyone in Garbutt looking to source PT-141 (Bremelanotide), the foundational reality is that this compound is available only through an online research supply market. The practical takeaway for Garbutt researchers: sourcing PT-141 (Bremelanotide) depends entirely on vendor quality evaluation, not geography — and the quality verification approach is the same regardless of where you are. What consistently distinguishes top PT-141 (Bremelanotide) vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for contamination assurance. What follows is a sourcing and quality evaluation guide built specifically around PT-141 (Bremelanotide), covering everything a Garbutt researcher needs to source confidently.
What Studies Say About PT-141 (Bremelanotide)
PT-141 (Bremelanotide) falls within a class of peptides studied for dermatological and aesthetic biology applications. GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is one of the most extensively studied cosmetic peptides, with documented activity in promoting collagen I and collagen III synthesis in fibroblast cultures, activating antioxidant enzymes, and promoting wound healing. Its copper-chelating properties make it mechanistically distinct from non-metallopeptides in the aesthetic category. Melanotan-2 (MT-2) is a cyclic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that acts on melanocortin receptors — primarily MC1R in melanocytes for pigmentation effects and MC4R in the hypothalamus for other documented effects. For researchers in Garbutt studying skin biology, pigmentation, or melanocortin receptor pharmacology, these compounds offer mechanistically specific research tools.
How to Source PT-141 (Bremelanotide) — Vendor Guide
The most effective path to quality PT-141 (Bremelanotide) is community research first — peptide forums aggregate real purchasing experience that are more reliable than search results. When reviewing a PT-141 (Bremelanotide) COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are at acceptable levels for the intended application. The combination of community consensus and independent COA review is the most reliable sourcing approach — community feedback surfaces recurring issues no single purchase reveals, and vice versa. For Garbutt researchers making a first PT-141 (Bremelanotide) purchase: apply these quality criteria before ordering, begin with a small order, and check that batch numbers on your vial match the COA before use.
Order PT-141 (Bremelanotide) — ships to Garbutt
COA-verified · International tracking · Research grade
PT-141 (Bremelanotide) is available for research use only and is not approved for human use by the FDA or comparable health authorities — all information here is provided for educational purposes. Storage requirements for PT-141 (Bremelanotide): lyophilised powder at minus 20°C, reconstituted solution kept at 2-8°C refrigerated and finished within 30 days of reconstitution; reconstitute only with sterile bacteriostatic water. Verify the endotoxin level in your PT-141 (Bremelanotide) batch COA before use in any in-vivo protocol — look for results stated as EU/mg and verify they are within the acceptable range for your research context. Researchers running multi-compound protocols with PT-141 (Bremelanotide) should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What is PT-141?
PT-141 (Bremelanotide) is a cyclic melanocortin receptor agonist developed from Melanotan-2. Unlike MT-2, PT-141 acts primarily on MC3R and MC4R receptors in the CNS rather than MC1R in melanocytes. It received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. As a research compound it is studied for melanocortin receptor pharmacology.
What is the regulatory status of PT-141?
PT-141 (as Bremelanotide/Vyleesi) is an FDA-approved pharmaceutical in the US for HSDD in premenopausal women. This pharmaceutical status means it is more tightly regulated than pure research compounds in most jurisdictions. Import and possession regulations vary by country — verify current status in your jurisdiction before ordering.
How does PT-141 differ from Melanotan-2?
Both are melanocortin receptor agonists, but PT-141 is more selective for MC3R/MC4R (CNS-expressed receptors) while MT-2 has broader activity including MC1R (melanocytes) for pigmentation. PT-141 was specifically developed from MT-2 to have the CNS effects with reduced pigmentation side effects.
